Evidence map›Paper›PMID 35382049›Full record

ArticleThe Pan African medical journal2022

Speciation and antifungal susceptibility of

Victor Moses Musyoki, Winnie Mutai, Nancy Ngugi, Fredrick Otieno, Moses Muia Masika

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. A Cross-Sectional Study to DetermineBioMed research international · 2026
    Article
  5. Antimicrobial Resistance in Sub-Saharan Africa: A Comprehensive Landscape Review.The American journal of tropical medicine and hygiene · 2025
    Review
  6. Article
  7. Clinic-mycological spectrum ofCurrent medical mycology · 2023
    Article
  8. Article
  9. Article
  10. Current research on fungi in chronic wounds.Frontiers in molecular biosciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Victor Moses MusyokiDepartment of Medical Microbiology, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya.
Winnie MutaiDepartment of Medical Microbiology, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya.
Nancy NgugiDepartment of Medicine, Kenyatta National Hospital, Nairobi, Kenya.
Fredrick OtienoDepartment of Clinical Medicine and Therapeutics, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya.
Moses Muia MasikaDepartment of Medical Microbiology, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya.
University of Nairobi · KEKenyatta National Hospital · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: diabetic foot ulcer is the leading cause of hospital admissions, lower limb amputation and death among diabetic patients. Little information is available on fungal isolation in diabetic foot ulcer patients, especially in sub-Saharan Africa. This study aimed to describe Candida species infecting diabetic foot ulcers in patients receiving clinical care at Kenyatta National Hospital and assess their antifungal susceptibility profile. Methods: this was a cross-sectional study carried out at Kenyatta National Hospital among adult diabetic foot ulcer patients over a three-month period. Species identification of Candida was performed using VITEK - 2 System and further confirmed by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. Antifungal susceptibility testing was determined using VITEK-2 System. Data were analysed using WHONET and SPSS. Results: among the 152 study patients recruited, 98% (n=149) had type 2 diabetes. Sixty one percent of the participants were male. The mean age of the study participants was 50.7 years (SD 12.9). A total of 36 Candida species were isolated, of which 75% (n=27) were Candida albicans. Candida lusitaniae (8%, n=3) and C. dubliniensis (5%, n=2) were the predominant non-albicans Candida species. The overall prevalence of diabetic foot ulcer candidiasis was 20% (n=31). C. albicans isolates (26%) were resistant to caspofungin, fluconazole, micafungin, and voriconazole but highly susceptible to amphotericin B and flucytosine (81-96%). Non-albicans Candida species isolated were susceptible (90-100%) to a majority of the antifungal agents tested. Conclusion: Candida albicans was the predominant species isolated and showed low resistance rates to the commonly administered antifungal agents. There is need to include fungal diagnosis in the investigation of diabetic foot ulcer infection.

Indexed as

Diabetes Mellitus, Type 2Diabetic FootAdultAntifungal AgentsCandidaCross-Sectional StudiesDrug Resistance, FungalFluconazoleHumansKenyaMaleMicrobial Sensitivity TestsMiddle AgedTertiary Care CentersAntifungal AgentsFluconazoleantifungal resistanceCandida speciesDiabetic foot ulcerFungisusceptibility

Identifiers

PMID35382049
PMCPMC8956903
OpenAlexW4206030151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.